You can buy or sell PTGX and other stocks, options, ETFs, and crypto commission-free!
Protagonist Therapeutics, Inc. Common Stock, also called Protagonist Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Read More The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 8
Protagonist expands PTG-200 deal with Janssen; shares up 13%
Thinly traded micro cap Protagonist Therapeutics (PTGX +12.8% ) is up on below-average volume on the heels of its expanded license and collaboration agreement with Johnson & Johnson (JNJ +0.1% ) unit Janssen Biotech to co-develop and commercialize PTG-200 for all indications, including inflammatory bowel disease.
Yahoo FinanceMay 8
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 8
What You Must Know About Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Beta Value
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific...
-$0.59 per share
-$0.58 per share